The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area. Launch results have been mixed with both instant successes and slow starters.
Recent market entries have illustrated that there are a critical core set of factors for cardiovascular products as well as other therapeutic areas: the ability to differentiate, a defined target patient population, investment in launch activities, engagement of thought leaders, education of key stakeholders, demonstration of value, utilization of new technologies and avoidance of launch pitfalls.
Best Practices, LLC's report, Success Factors and Failure Points in Cardiovascular Product Launches, explores each aspect of this framework for launch success and provides a cardiovascular segment as well as a data segment representing other therapeutic areas combined. This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.
In addition, the study presents launch leaders' perspective on the current and future risk levels for an array of pitfall factors that can affect a launch, from patient and payer to physician and regulatory.